News 2010 -

June 2010 - On June 2, 2010, CardioPolymers, Inc. completed a merger with LoneStar Heart, Inc. and became a fully owned subsidiary of that company. With its new parent, CardioPolymers will continue to develop its lead product for Congestive Heart Failure while benefiting from a significant technology pipeline. Check back for more details on the merger in the near future..

February 2010 - Positive outcomes for the first six patients treatd with Algisyl-LVR at the German Heart Center in Munich are presented at the annual meeting of the German Society for Thorax, Heart, and Vascular Surgery (DGTHG) held in Stuttgart.

February 2009 - CardioPolymers' first patient successfully treated with Algisyl-LVR at the German Heart Center in Munich.

January 2009 - CardioPolymers receives IRB approval from German Heart Center in Munich for first-in-man Algisyl-LVR study.

December 2008 – CardioPolymers files IDE with US FDA for its Algisyl-LVR heart failure therapy with a view toward initiating a multi-center U.S. study in mid 2009.

December 2008 – CardioPolymers files for IRB and EU approval at three centers in Europe for its initial clinical study for Algisyl-LVR in patients undergoing open chest CABG or valve surgery.

June 2008 – CardioPolymers conducts pre-IDE meeting with US FDA for its Algisyl-LVR heart failure therapy.

May 2008 – CardioPolymers completes 32 patient safety study for its Plexisyl-AF product for the prevention of post-operative atrial fibrillation. IDE filing with U.S. FDA scheduled for early 2009.

February 2008 – CardioPolymers begins, at five world class heart centers in Germany, a 32 patient ‘randomized safety study’ for its Plexisyl-AF product for the prevention of post-operative atrial fibrillation in patients undergoing open chest cardiothoracic procedures using its second generation biomaterial.

January 2008 - CardioPolymers and ANGIOTECH Pharmaceuticals sign exclusive license agreement to utilize Angiotech’s implantable biodegradable polymer for the prevention of post-operative atrial fibrillation

September 2007 – CardioPolymers conducts pre-IDE meeting with US FDA for a multi-center U.S. clinical study for its Plexisyl-AF product for the prevention of post-operative atrial fibrillation.

June 2007 – CardioPolymers completes its large animal pre-clinical Algisyl-LVR validation study conducted by Dr. Hanni Sabbah, Ph.D. at Henry Ford Hospital Cardiac Research Center in Detroit.

May 2007 - CardioPolymers completes large animal pre-clinical study on its second generation biopolymer for its Plexisyl-AF product for the prevention of post-operative atrial fibrillation.

March 2007 - CardioPolymers completes European multi-center 54 patient clinical study using first generation biopolymer for post-operative atrial fibrillation.

Feb 2007 – CardioPolymers receives device classification from US FDA for its Algisyl-LVR product for the treatment of congestive heart failure and also for its Plexisyl-AF product for the prevention of post-operative atrial fibrillation.